Annales De Dermatologie Et De Venereologie最新文献

英文中文

Internalized stigma, disease severity, quality of life, anxiety and depression in axillary hyperhidrosis 腋窝多汗症患者的内化耻辱感、疾病严重程度、生活质量、焦虑和抑郁

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103291

Ş. Gökşin , I.G. İmren

Background

Axillary hyperhidrosis (AH) is characterized by excessive underarm sweating. It is a chronic autonomic disorder that can lead to social embarrassment, impaired quality of life (QoL), anxiety and depression. Internalized stigma (IS), defined as the acceptance of negative societal attitudes and stereotypes about an individual’s illness, has not been previously studied in AH. The aim of this study was to evaluate the level of IS in patients with AH and the relationships between IS, disease severity, quality of life, anxiety, and depression.

Patients and methods

One hundred and four patients with AH were included in the study. Demographic and clinical characteristics of the patients were recorded. The Hyperhidrosis Disease Severity Scale (HDSS) was used to define disease severity. Assessment was made using the Internalized Stigma Scale (ISS) (between 29 and 116, the higher the score the greater the stigma), Hospital Anxiety and Depression Scale (HADS) and Dermatology Life Quality Index (DLQI).

Results

The mean age of the patients was 34.1 ± 10.9 years. The HDSS grade was mostly moderate to severe. The mean ISS score was 57.5 ± 6.5. Median HADS scores were 7 [interquartile range (IQR) 2–12] and 5 [IQR 2–10], respectively. HADS scores ≥ 8 were observed respectively in 39.4% and 8.7% of patients. The median DLQI score was 14 [IQR 4–24]. A DLQI score ≥ 11 was observed in 75% of patients. Significant correlation was found between ISS score and HDSS (r = 0.445, p < 0.001), HADS-A (r = 0.455, p < 0.001), DLQI (r = 0.478, p < 0.001) scores and symptom duration (r = 0.207, p = 0.035). The relationship between ISS and HADS depression scores was not statistically significant.

Conclusion

IS is common in patients with AH. Disease severity, symptom duration and anxiety increased IS. Patient’s quality of life is reduced in AH.

背景腋下多汗症（AH）的特征是腋下出汗过多。它是一种慢性自律神经失调症，可导致社交尴尬、生活质量（QoL）受损、焦虑和抑郁。内化成见（IS）被定义为接受社会对个人疾病的负面态度和刻板印象，此前尚未对腋下多汗症进行过研究。本研究旨在评估 AH 患者的内化成见水平，以及内化成见、疾病严重程度、生活质量、焦虑和抑郁之间的关系。研究记录了患者的人口统计学特征和临床特征。多汗症疾病严重程度量表（HDSS）用于定义疾病的严重程度。使用内化耻辱感量表（ISS）（29-116分之间，分数越高耻辱感越强）、医院焦虑抑郁量表（HADS）和皮肤科生活质量指数（DLQI）进行评估。HDSS 分级大多为中度至重度。平均 ISS 得分为 57.5 ± 6.5。HADS评分中位数分别为7[四分位距（IQR）2-12]和5[IQR 2-10]。HADS评分≥8分的患者分别占39.4%和8.7%。DLQI 评分的中位数为 14 [IQR 4-24]。75%的患者 DLQI 得分≥11。ISS评分与HDSS（r = 0.445，p <0.001）、HADS-A（r = 0.455，p <0.001）、DLQI（r = 0.478，p <0.001）评分和症状持续时间（r = 0.207，p = 0.035）之间存在显著相关性。ISS与HADS抑郁评分之间的关系无统计学意义。疾病严重程度、症状持续时间和焦虑增加了 ISS。AH患者的生活质量下降。

{"title":"Internalized stigma, disease severity, quality of life, anxiety and depression in axillary hyperhidrosis","authors":"Ş. Gökşin , I.G. İmren","doi":"10.1016/j.annder.2024.103291","DOIUrl":"10.1016/j.annder.2024.103291","url":null,"abstract":"<div><h3>Background</h3><p>Axillary hyperhidrosis (AH) is characterized by excessive underarm sweating. It is a chronic autonomic disorder that can lead to social embarrassment, impaired quality of life (QoL), anxiety and depression. Internalized stigma (IS), defined as the acceptance of negative societal attitudes and stereotypes about an individual’s illness, has not been previously studied in AH. The aim of this study was to evaluate the level of IS in patients with AH and the relationships between IS, disease severity, quality of life, anxiety, and depression.</p></div><div><h3>Patients and methods</h3><p>One hundred and four patients with AH were included in the study. Demographic and clinical characteristics of the patients were recorded. The Hyperhidrosis Disease Severity Scale (HDSS) was used to define disease severity. Assessment was made using the Internalized Stigma Scale (ISS) (between 29 and 116, the higher the score the greater the stigma), Hospital Anxiety and Depression Scale (HADS) and Dermatology Life Quality Index (DLQI).</p></div><div><h3>Results</h3><p>The mean age of the patients was 34.1 ± 10.9 years. The HDSS grade was mostly moderate to severe. The mean ISS score was 57.5 ± 6.5. Median HADS scores were 7 [interquartile range (IQR) 2–12] and 5 [IQR 2–10], respectively. HADS scores ≥ 8 were observed respectively in 39.4% and 8.7% of patients. The median DLQI score was 14 [IQR 4–24]. A DLQI score ≥ 11 was observed in 75% of patients. Significant correlation was found between ISS score and HDSS (r = 0.445, p < 0.001), HADS-A (r = 0.455, p < 0.001), DLQI (r = 0.478, p < 0.001) scores and symptom duration (r = 0.207, p = 0.035). The relationship between ISS and HADS depression scores was not statistically significant.</p></div><div><h3>Conclusion</h3><p>IS is common in patients with AH. Disease severity, symptom duration and anxiety increased IS. Patient’s quality of life is reduced in AH.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"151 3","pages":"Article 103291"},"PeriodicalIF":3.1,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leech therapy: A new treatment for non-infectious paronychia? 水蛭疗法：非感染性副癣的新疗法？

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103296

C. Arnal, B. Richert

引用次数: 0

From Delphi consensus to decision algorithm: Ethical considerations 从德尔菲共识到决策算法：伦理考虑

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103294

A. Petit

引用次数: 0

The value of alpha-1 antitrypsin functional testing and genotyping for the diagnosis of the MS variant of alpha-1 antitrypsin deficiency-associated panniculitis α-1抗胰蛋白酶功能测试和基因分型对诊断α-1抗胰蛋白酶缺乏症相关性泛发性皮炎的MS变异型的价值

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103295

S. Perez, J.-D. Bouaziz, A. Petit, M. Battistella, T. Mahévas

引用次数: 0

Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm 成人中重度银屑病的治疗：使用德尔菲法制定决策算法的专家共识声明

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103287

F. Poizeau , S. Leducq , L. Fardet , M. Beylot-Barry , Guillaume Chaby , M. Chastagner , F. Corgibet , L. Gouillon , N. Jouan , D. Jullien , A. Acher , F. Amatore , J.-M. Amici , H. Aubert , F. Aubin , N. Beneton , D Bouilly , A.-C. Bursztejn , C. Buzenet , M. Chamaillard-Pujol , B. Guillot

Background

New highly effective drugs for moderate-to-severe cutaneous psoriasis are regularly marketed, and the hierarchy of treatments thus requires frequent review.

Objectives

A Delphi method was used to enable a structured expert consensus on the use of systemic treatments and phototherapy among adults with moderate-to-severe psoriasis.

Methods

The Delphi method consists in achieving a convergence of opinions among a panel of experts using several rounds of questionnaires with controlled feedback between rounds. A two-part Delphi questionnaire was administered online to French psoriasis experts. In the first part, 180 items related to the prescription of systemic treatments and phototherapy for adult patients with moderate-to-severe psoriasis were grouped into 21 sections covering different lines of treatment and different forms of cutaneous psoriasis. The experts voted on each proposal using an ordinal 7-point Likert scale. The second part comprised 11 open-ended questions about special indications for each therapeutic class. These were converted into 101 questions for subsequent rounds. Consensus was deemed to have been reached if more than 80% of the experts agreed with a given proposal.

Results

Three rounds of questionnaires were sequentially sent to 35 participants between November 2021 and March 2022. Thirty-three (94%) completed all three rounds. For plaque psoriasis, only methotrexate was recommended by the experts as first-line systemic treatment (89% of votes). Cyclosporin was advocated in pustular and erythrodermic psoriasis, and acitretin was suggested for hyperkeratotic and palmoplantar psoriasis. In the event of failure of or intolerance to non-biological systemic treatments, guselkumab, risankizumab, ixekizumab or secukinumab were recommended by more than 80% of the experts. Tumor Necrosis Factor (TNF) inhibitors remain useful for patients with cardiovascular risk factors. Special indications were provided for each therapeutic class (methotrexate/narrowband ultraviolet B phototherapy, psoralen/ultraviolet A phototherapy, cyclosporin, acitretin, apremilast, TNF inhibitors, interleukin (IL)-12/23 inhibitors, IL-17(R)A inhibitors, and IL-23 inhibitors).

Conclusions

This expert consensus statement indicate that newly available IL-17 and IL-23 inhibitors may be favored over TNF and IL-12/23 inhibitors as first-line biologics. The Centre of Evidence of the French Society of Dermatology has drawn up a decision-making algorithm to guide clinicians in the therapeutic management of moderate-to-severe psoriasis.

背景治疗中重度皮肤银屑病的新型高效药物不断上市，因此需要经常对治疗方法的等级进行审查。方法德尔菲法是通过多轮问卷调查并在两轮调查之间控制反馈，使专家小组的意见趋于一致。我们在网上向法国银屑病专家发放了一份由两部分组成的德尔菲问卷。在第一部分中，与中重度银屑病成人患者的系统治疗和光疗处方相关的 180 个项目被分为 21 个部分，涵盖了不同的治疗方法和不同形式的皮肤银屑病。专家们采用 7 分制李克特量表对每项建议进行投票。第二部分包括 11 个开放式问题，涉及每个治疗类别的特殊适应症。这些问题被转换成 101 个问题，供后续轮次使用。结果2021年11月至2022年3月期间，向35名参与者依次发送了三轮问卷。33人（94%）完成了全部三轮问卷。对于斑块状银屑病，专家只推荐甲氨蝶呤作为一线系统治疗（89% 的投票）。环孢素被推荐用于脓疱型和红皮病型银屑病，阿曲汀被推荐用于角化过度型和掌跖银屑病。如果对非生物制剂系统治疗失败或不耐受，80% 以上的专家建议使用 guselkumab、risankizumab、ixekizumab 或 secukinumab。肿瘤坏死因子（TNF）抑制剂对有心血管风险因素的患者仍然有用。每一类治疗药物（甲氨蝶呤/窄带紫外线B光疗、补骨脂素/紫外线A光疗、环孢素、阿昔替丁、阿普仑司特、TNF抑制剂、白细胞介素（IL）-12/23抑制剂、IL-17（R）A抑制剂和IL-23抑制剂）都有特殊适应症。结论该专家共识声明表明，作为一线生物制剂，新上市的IL-17和IL-23抑制剂可能比TNF和IL-12/23抑制剂更受青睐。法国皮肤病学会证据中心（Centre of Evidence of the French Society of Dermatology）制定了一套决策算法，以指导临床医生对中重度银屑病进行治疗管理。

{"title":"Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm","authors":"F. Poizeau , S. Leducq , L. Fardet , M. Beylot-Barry , Guillaume Chaby , M. Chastagner , F. Corgibet , L. Gouillon , N. Jouan , D. Jullien , A. Acher , F. Amatore , J.-M. Amici , H. Aubert , F. Aubin , N. Beneton , D Bouilly , A.-C. Bursztejn , C. Buzenet , M. Chamaillard-Pujol , B. Guillot","doi":"10.1016/j.annder.2024.103287","DOIUrl":"10.1016/j.annder.2024.103287","url":null,"abstract":"<div><h3>Background</h3><p>New highly effective drugs for moderate-to-severe cutaneous psoriasis are regularly marketed, and the hierarchy of treatments thus requires frequent review.</p></div><div><h3>Objectives</h3><p>A Delphi method was used to enable a structured expert consensus on the use of systemic treatments and phototherapy among adults with moderate-to-severe psoriasis.</p></div><div><h3>Methods</h3><p>The Delphi method consists in achieving a convergence of opinions among a panel of experts using several rounds of questionnaires with controlled feedback between rounds. A two-part Delphi questionnaire was administered online to French psoriasis experts. In the first part, 180 items related to the prescription of systemic treatments and phototherapy for adult patients with moderate-to-severe psoriasis were grouped into 21 sections covering different lines of treatment and different forms of cutaneous psoriasis. The experts voted on each proposal using an ordinal 7-point Likert scale. The second part comprised 11 open-ended questions about special indications for each therapeutic class. These were converted into 101 questions for subsequent rounds. Consensus was deemed to have been reached if more than 80% of the experts agreed with a given proposal.</p></div><div><h3>Results</h3><p>Three rounds of questionnaires were sequentially sent to 35 participants between November 2021 and March 2022. Thirty-three (94%) completed all three rounds. For plaque psoriasis, only methotrexate was recommended by the experts as first-line systemic treatment (89% of votes). Cyclosporin was advocated in pustular and erythrodermic psoriasis, and acitretin was suggested for hyperkeratotic and palmoplantar psoriasis. In the event of failure of or intolerance to non-biological systemic treatments, guselkumab, risankizumab, ixekizumab or secukinumab were recommended by more than 80% of the experts. Tumor Necrosis Factor (TNF) inhibitors remain useful for patients with cardiovascular risk factors. Special indications were provided for each therapeutic class (methotrexate/narrowband ultraviolet B phototherapy, psoralen/ultraviolet A phototherapy, cyclosporin, acitretin, apremilast, TNF inhibitors, interleukin (IL)-12/23 inhibitors, IL-17(R)A inhibitors, and IL-23 inhibitors).</p></div><div><h3>Conclusions</h3><p>This expert consensus statement indicate that newly available IL-17 and IL-23 inhibitors may be favored over TNF and IL-12/23 inhibitors as first-line biologics. The Centre of Evidence of the French Society of Dermatology has drawn up a decision-making algorithm to guide clinicians in the therapeutic management of moderate-to-severe psoriasis.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"151 3","pages":"Article 103287"},"PeriodicalIF":3.1,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0151963824000437/pdfft?md5=fcaadc1a0da475739a7b367b4cdb337a&pid=1-s2.0-S0151963824000437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141623750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Léonie Martin, Sister Françoise-Thérèse (1863–1941), may have had atopic eczema 弗朗索瓦丝-泰雷兹修女莱奥妮-马丁（1863-1941 年）可能患有特应性湿疹

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-15 DOI: 10.1016/j.annder.2024.103292

N. Kluger, P. Charlier

引用次数: 0

Changes in the gut microbiota of pseudoxanthoma elasticum patients 假黄瘤患者肠道微生物群的变化

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-14 DOI: 10.1016/j.annder.2024.103290

M. Berard , K. Chassain , C. Méry , F. Gillaizeau , T. Carton , H. Humeau , N. Navasiolava , S. Rocour , L. Schurgers , M. Kempf , L. Martin

Objective

Pseudoxanthoma elasticum (PXE) is a rare autosomal disorder with a variable phenotype that may be modulated by environmental factors. Plasma vitamin K (VK) levels may be involved in the ectopic calcification process observed in PXE. Since VK2 is predominantly produced by the gut microbiota, we hypothesized that changes in the gut microbiota of PXE patients might exacerbate the calcification process and disease symptoms.

Methods

Twenty PXE patients were included in the study and 60 gut microbiota profiles from the Biofortis laboratory database were used as controls.

Results

The Rhodospirillaceae family was more abundant in the PXE group while the Sphingomonadaceae family was more abundant in the control group. In a PXE severity subgroup analysis, microbiota dispersion was lower in “severe” than in “non-severe” patients, which was confirmed by permutation multivariate analysis of variance at the phylum, family and genus ranks. However, no significant association was found in a model incorporating relative abundance of bacterial families, severity score, and different blood and fecal VK species.

Conclusion

These results suggest slight compositional changes in the gut microbiota of PXE patients. Further studies are needed to substantiate their impact on VK metabolism and the calcification process.

目的假黄疽（PXE）是一种罕见的常染色体疾病，其表型多变，可能受环境因素的影响。血浆维生素 K（VK）水平可能与 PXE 中观察到的异位钙化过程有关。由于 VK2 主要由肠道微生物群产生，我们推测 PXE 患者肠道微生物群的变化可能会加剧钙化过程和疾病症状。结果在 PXE 组中，Rhodospirillaceae 家族的数量较多，而在对照组中，Sphingomonadaceae 家族的数量较多。在 PXE 严重程度亚组分析中，"重度 "患者的微生物群分散度低于 "非重度 "患者，这一点在门、科和属的包络多变量方差分析中得到了证实。结论：这些结果表明，PXE 患者肠道微生物群的组成发生了轻微变化。这些结果表明 PXE 患者肠道微生物群的组成发生了轻微变化，需要进一步研究以证实其对 VK 代谢和钙化过程的影响。

{"title":"Changes in the gut microbiota of pseudoxanthoma elasticum patients","authors":"M. Berard , K. Chassain , C. Méry , F. Gillaizeau , T. Carton , H. Humeau , N. Navasiolava , S. Rocour , L. Schurgers , M. Kempf , L. Martin","doi":"10.1016/j.annder.2024.103290","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103290","url":null,"abstract":"<div><h3>Objective</h3><p>Pseudoxanthoma elasticum (PXE) is a rare autosomal disorder with a variable phenotype that may be modulated by environmental factors. Plasma vitamin K (VK) levels may be involved in the ectopic calcification process observed in PXE. Since VK2 is predominantly produced by the gut microbiota, we hypothesized that changes in the gut microbiota of PXE patients might exacerbate the calcification process and disease symptoms.</p></div><div><h3>Methods</h3><p>Twenty PXE patients were included in the study and 60 gut microbiota profiles from the Biofortis laboratory database were used as controls.</p></div><div><h3>Results</h3><p>The <em>Rhodospirillaceae</em> family was more abundant in the PXE group while the <em>Sphingomonadaceae</em> family was more abundant in the control group. In a PXE severity subgroup analysis, microbiota dispersion was lower in “severe” than in “non-severe” patients, which was confirmed by permutation multivariate analysis of variance at the phylum, family and genus ranks. However, no significant association was found in a model incorporating relative abundance of bacterial families, severity score, and different blood and fecal VK species.</p></div><div><h3>Conclusion</h3><p>These results suggest slight compositional changes in the gut microbiota of PXE patients. Further studies are needed to substantiate their impact on VK metabolism and the calcification process.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"151 3","pages":"Article 103290"},"PeriodicalIF":3.1,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent cervical swelling syndrome as a rare cause of left supraclavicular edema: Case series and literature review 复发性颈椎肿胀综合征是左锁骨上水肿的罕见病因：病例系列和文献综述。

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-07-06 DOI: 10.1016/j.annder.2024.103286

E. Charvet , T. Mahévas , S. Rivière , D. Gobert , V. Jachiet , V. Panayotopoulos , N. Abisror , E. Ghrenassia , L. Arrive , S. Vignes , A. Mekinian , O. Fain

引用次数: 0

Isotretinoin: Past, present and future. A French perspective 异维A酸：过去、现在和未来。法国视角。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-06-07 DOI: 10.1016/j.annder.2023.103244

S. Leducq , F. Poizeau , G. Chaby , J. Tannous , F. Ballanger-Desolneux , E. Baubion , A. Bertolotti , O. Cogrel , C. Droitcourt , V. Garnier , S. Gautier , L. Hefez , C. Hotz , A.-P. Jonville-Béra , N. Jouan , A. Mahé , E. Mahé , G. Martinho , J. Micallef , T. Puszkarek , O. Chosidow

引用次数: 0

French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis) 法国国家成人表皮坏死症（史蒂文斯-约翰逊综合征和中毒性表皮坏死症）诊断和管理规程

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-05-28 DOI: 10.1016/j.annder.2024.103282

S. Ingen-Housz-Oro , I. Matei , A. Gaillet , J. Gueudry , K. Zaghbib , H. Assier , C. Hua , B. Bensaid , A. Colin , R. Ouedraogo , J. Redlich , E. Courtois , K. Chazelas , E. Sbidian , L. Nakad , E. Bequignon , N. Terkmane , F. Gaultier , F. Schlemmer , G. Do-Pham , N. de Prost

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀